azacitidin ideogen 100 mg pulver zur herstellung einer injektionssuspension
azacitidin ideogen 100 mg poudre pour la fabrication d'une suspension injectable
azacitidin spirig hc 100 mg pulver zur herstellung einer injektionssuspension
azacitidin spirig hc 100 mg poudre pour la fabrication d'une suspension injectable
azacitidin stada 100 mg pulver zur herstellung einer injektionssuspension
azacitidin stada 100 mg poudre pour la fabrication d'une suspension injectable
azacitidin stada 150 mg pulver zur herstellung einer injektionssuspension
azacitidin stada 150 mg poudre pour la fabrication d'une suspension injectable
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - agenti antineoplastici - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leucemia, linfocitica, cronica, b-cell - agenti antineoplastici - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.